[go: up one dir, main page]

WO1996031206A2 - Flavones et coumarines utilisees en tant qu'agents dans le traitement de l'atherosclerose - Google Patents

Flavones et coumarines utilisees en tant qu'agents dans le traitement de l'atherosclerose Download PDF

Info

Publication number
WO1996031206A2
WO1996031206A2 PCT/US1996/004028 US9604028W WO9631206A2 WO 1996031206 A2 WO1996031206 A2 WO 1996031206A2 US 9604028 W US9604028 W US 9604028W WO 9631206 A2 WO9631206 A2 WO 9631206A2
Authority
WO
WIPO (PCT)
Prior art keywords
chromen
phenyl
hydroxy
methoxy
methyl
Prior art date
Application number
PCT/US1996/004028
Other languages
English (en)
Other versions
WO1996031206A3 (fr
Inventor
Uday Saxena
Bharat Kalidas Trivedi
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Priority to AU52592/96A priority Critical patent/AU5259296A/en
Publication of WO1996031206A2 publication Critical patent/WO1996031206A2/fr
Publication of WO1996031206A3 publication Critical patent/WO1996031206A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 

Definitions

  • the present invention relates to pharmaceutical compositions which include these compounds and a pharmaceutically acceptable carrier for administering an effective amount of the aforementioned compounds in unit dosage form in the treatment methods mentioned above.
  • Atherosclerosis is viewed as a chronic inflammatory disease of the artery involving monocyte accumulation, smooth muscle proliferation, and cholesteryl ester accumulation by both these cell types.
  • Monocyte accumulation in atherosclerosis begins with the adherence of blood-borne monocytes to defined areas of aortic endothelium (Ross R., Nature, 1993;362:801-809) .
  • the attachment of monocytes is mediated by VCAM-1 expression on endothelial cell- surface as suggested by studies in animal models of atherosclerosis (Li H., et al . , Arteriosclerosis Throm.
  • flavones and/or coumarins are inhibitors of VCAM-1 and ICAM-1 and additionally are active in blocking leukocyte adhesion in a rat model and are thus useful as agents for the treatment of atherosclerosis, restenosis, and immune disorders such as arthritis and transplant rejection.
  • a still further embodiment of the present invention is a method of treatment of atherosclerosis in mammals in need thereof comprising administering to such mammal an effective amount of a compound selected from the group consisting of: a flavone and a coumarin in combination with one or more agents selected from the group consisting of: (a) ACAT inhibitor; (b) HMG-CoA reductase inhibitor;
  • cycloalkyl means a saturated hydrocarbon ring which contains from 3 to 12 carbon atoms, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, adamantyl, and the like.
  • alkoxy and thioalkoxy are O-alkyl or
  • flavone means 2-phenyl-4H-l-benzopyran- 4-one or a substituted 2-phenyl-4H-l-benzopyran-4-one, i.e. ,
  • R is hydrogen, alkyl, alkoxy, hydroxy, -N-R 10 wherein R 10 and R 11 are each R 11 independently the same or different and each is hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, or
  • R 2 and R 3 may be joined to form a ring selected from the group consisting of: further, R 2 and R 3 or R 7 and R 8 may be joined by a methylenedioxy group; and in a compound of Formula II R is hydrogen, aryl, arylalkyl, -CH 2 -NH-CH 2 -phenyl,
  • R 2 , R 3 , R 4 , and R 5 are each independently the same or different, and each is hydrogen, alkyl, methoxy, halogen, hydroxy,
  • R 3 and R 4 may be joined to form a ring which is
  • Particularly valuable compounds of Formula I and Formula II are selected from the group consisting of:
  • 6-Chloro-2- (5-chloro-2-hydroxy-phenyl) -chromen- 4-one; 2- (2-Amino-phenyl) -chromen-4-one; 6-Bromo-2- (3 -hydroxy-4-methoxy-phenyl ) -chromen- -one ;
  • Preferred compounds used in the second embodiment of the present invention include one or more agents selected from the group consisting of an acyl CoA:cholesterol acyltransferase (ACAT) inhibitor;
  • ACAT acyl CoA:cholesterol acyltransferase
  • HMG-CoA reductase 3-hydroxy-3-methyglutaryl-coenzyme A reductase (HMG-CoA reductase) inhibitor; lipid regulator; and bile acid sequestrant.
  • ACAT inhibitors include DL-melinamide disclosed in British Patent 1,123,004 and Japan. J. Pharmacol. , 1986;42:517-523; 2, 2-dimethyl-N- (2, 4, 6- trimethoxyphenyDdodecanamide disclosed in U.S. Patent 4,716,175; N- [2, 6-bis (1-methylethyl)phenyl] -N' - [ [1- (4-dimethylaminophenyl) cyclopentyl]methyl]urea disclosed in U.S.
  • Patent 5,015,644; 2, 6-bis (1-methyl- ethyl)phenyl[[2,4, 6-tris (1-methylethyl)phenyl]acetyl] - sulfamate disclosed in copending U.S. Patent Application Serial Number 08/233,932 filed April 13, 1994; and the like.
  • U.S. Patents 4,716,175 and 5,015,644 and U.S. Patent Application Serial Number 08/233,932 and British Patent 1,123,004 and Japan. J. Pharmacol.. 1986;42:517-523 are hereby incorporated by reference.
  • HMG-CoA reductase inhibitors include lovastatin disclosed in U.S. Patent 4,231,938; pravastatin disclosed in U.S. Patent 4,346,227; simvastatin disclosed in U.S. Patent 4,444,784; fluvastatin disclosed in U.S. Patent 4,739,073; atorvastatin disclosed in U.S. Patents 4,681,893 and 5,273,995; and the like.
  • U.S. Patents 4,231,938, 4,346,227, 4,444,784, 4,681,893, 4,739,073, and 5,273,995 are hereby incorporated by reference.
  • bile acid sequestrants include colestipol disclosed in U.S. Patents 3,692,895 and 3,803,237; cholestyramine disclosed in U.S. Patent 3,383,281 and Casdorph R. in Lipid Pharmacology..
  • U.S. Patents 3,692,895, 3,803,237, and 3,383,281 and R. Casdorph, supra, 1976, are hereby incorporated by reference.
  • Examples of lipid regulators include gemfibrozil described in U.S. Patent 3,674,836; bezafibrate disclosed in U.S. Patent 3,781,328; clofibrate disclosed in U.S. Patent 3,262,850; fenofibrate disclosed in U.S. Patent 4,058,552; niacin disclosed in McElvain, et al . , Or ⁇ . Svn.. 1925;4:49; and the like.
  • the flavones and coumarins of the present invention are prepared by standard procedures known to those skilled in the art. For example, methods of preparing flavones are disclosed in "The Flavonoids" eds . , Harborne J.B. , Marby T.J. , and Marby H. , Chapman and Hall, London 1975:693-707; Banerji A., and Goomer N.C., Synthesis. 1980:874; Allan J. and Robinson R. , J. Chem. Soc . , 1926; 129 :2334;
  • the flavones and coumarins are valuable agents for the treatment of atherosclerosis, restenosis, and immune disorders such as arthritis and transplant rejection.
  • the tests employed indicate that the compounds possess activity against VCAM-1 and ICAM-1.
  • FBS fetal bovine serum
  • TNF recombinant Tumor necrosis factor-alpha (Genzyme!
  • BSA Bovine serum albumin
  • Anti-ICAM-1 antibody R&D System, BBA#3
  • Anti-VCAM-1 antibody (R&D System, BBA#6)
  • HAEC Human aortic endothelial cells
  • the cells were incubated with anti-VCAM-1 monoclonal antibody (1.25 ⁇ g/mL) for 2 hours at 37°C. The unbound antibody was aspirated, cells washed
  • Anti-ICAM-1 monoclonal antibody (0.5 ⁇ g/mL) was added to the cells and incubated for 2 hours at 37°C. The media was aspirated, cells washed 4 times with 2% BSA-DMEM, and second antibody added (sheep anti-mouse IgG, 1:3000 dilution) , and cells incubated for 1 hour at 37°C. After removal of the unbound antibody and 4 washes with DMEM alone, the cells were incubated with the HRP color reagent for 15 minutes at 37°C in the dark. Fifty microliters of the color reagent from each well was transferred to 96 well plates and absorbance read at 414 run on a Titertek ELISA reader. Cell- surface ICAM-1 expression is presented as OD 414 . The data in the table show the VCAM-1 and ICAM-1 activity of representative flavones and coumarins of the present invention.
  • the lungs and hearts are placed in separate tubes containing 3 mL of a solution of normal saline containing 1 mg/mL of aprotinin and phenylmethyl sulfonyl fluoride (PMSF) .
  • the tissue is then homogenized using a polytron on the high setting. All samples are held on ice. The samples are then aliquoted and frozen at 20°C.
  • the myeloperoxidase assay was standardized with the linear portion of the curve identified. Lowry protein assays were performed and the samples were diluted to obtain optical densities in the linear range.
  • Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents .
  • viscous material such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents .
  • solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for oral administration.
  • Such liquid forms include solutions, suspensions, and emulsions.
  • These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Les flavones et les coumarines ou leurs sels pharmaceutiquement acceptables sont des inhibiteurs de VCAM-1 et ICAM-1 et sont donc utiles dans le traitement de l'athérosclérose, de la resténose et de troubles immunitaires tels que l'arthrite et le rejet des transplantations.
PCT/US1996/004028 1995-04-07 1996-03-25 Flavones et coumarines utilisees en tant qu'agents dans le traitement de l'atherosclerose WO1996031206A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU52592/96A AU5259296A (en) 1995-04-07 1996-03-25 Flavones and coumarins as agents for the treatment of athero sclerosis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41870995A 1995-04-07 1995-04-07
US08/418,709 1995-04-07

Publications (2)

Publication Number Publication Date
WO1996031206A2 true WO1996031206A2 (fr) 1996-10-10
WO1996031206A3 WO1996031206A3 (fr) 1996-12-12

Family

ID=23659261

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/004028 WO1996031206A2 (fr) 1995-04-07 1996-03-25 Flavones et coumarines utilisees en tant qu'agents dans le traitement de l'atherosclerose

Country Status (2)

Country Link
AU (1) AU5259296A (fr)
WO (1) WO1996031206A2 (fr)

Cited By (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922719A (en) * 1997-08-11 1999-07-13 Warner-Lambert Company Coumarin dopamine D4 receptor antagonists
WO1999054286A2 (fr) * 1998-04-17 1999-10-28 Parker Hughes Institute Inhibiteurs btk et leurs procedes d'identification et d'utilisation
FR2781153A1 (fr) * 1998-07-15 2000-01-21 Lafon Labor Composition therapeutique a base de flavonoides destinee a etre utilisee dans le traitement des tumeurs par des agents cytotoxiques
US6020347A (en) * 1997-11-18 2000-02-01 Merck & Co., Inc. 4-substituted-4-piperidine carboxamide derivatives
WO2000019989A2 (fr) * 1998-10-02 2000-04-13 Grünenthal GmbH Utilisation de derives de catechine comme inhibiteurs de proteinase
US6069163A (en) * 1997-10-21 2000-05-30 Merck & Co., Inc. Azapeptide acids as cell adhesion inhibitors
WO2000035435A1 (fr) * 1998-12-15 2000-06-22 Warner-Lambert Company Technique de prevention du rejet de greffe par utilisation d'un inhibiteur du mek
US6090841A (en) * 1997-11-21 2000-07-18 Merck & Co., Inc. Substituted pyrrole derivatives as cell adhesion inhibitors
WO2000050030A1 (fr) * 1999-02-25 2000-08-31 Ted Ebendal Nouvelle utilisation
US6160010A (en) * 1998-08-21 2000-12-12 Parker Hughes Institute BTK inhibitors and methods for their identification and use
US6191171B1 (en) 1997-11-20 2001-02-20 Merck & Co., Inc. Para-aminomethylaryl carboxamide derivatives
US6221888B1 (en) 1997-05-29 2001-04-24 Merck & Co., Inc. Sulfonamides as cell adhesion inhibitors
US6291511B1 (en) 1997-05-29 2001-09-18 Merck & Co., Inc. Biarylalkanoic acids as cell adhesion inhibitors
US6291456B1 (en) 1998-12-30 2001-09-18 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
US6331562B1 (en) 1998-12-30 2001-12-18 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
WO2002102367A1 (fr) * 2001-06-19 2002-12-27 Tg Biotech, Inc. Composition pharmaceutique pour la prevention et le traitement de l'arthrite des articulations, et procede de criblage correspondant
WO2002102368A1 (fr) * 2001-06-19 2002-12-27 Tg Biotech, Inc. Procede de production cellulaire de masse de chondrocytes a l'aide d'un inhibiteur d'activite erk, et procede de criblage associe
US6645939B1 (en) 1997-11-24 2003-11-11 Merck & Co., Inc. Substituted β-alanine derivatives as cell adhesion inhibitors
EP1368024A1 (fr) * 2001-03-16 2003-12-10 Novogen Research Pty. Ltd. Traitement de la restenose
JP2004509855A (ja) * 2000-07-21 2004-04-02 中外製薬株式会社 ＴＮＦαインヒビターとして有用なクマリン誘導体
JP2004123728A (ja) * 2002-09-09 2004-04-22 New Industry Research Organization 新規フラボノイド化合物及びその利用
WO2004041279A1 (fr) 2002-10-30 2004-05-21 Merck & Co., Inc. Modulateurs gamma-aminoamides de l'activite de recepteur de chimiokine
WO2004105769A1 (fr) * 2003-05-28 2004-12-09 Universite De Liege Composition pharmaceutique destinee au traitement et/ou a la prevention de l'atherosclerose d'origine infectieuse
EP1556031A2 (fr) * 2002-10-22 2005-07-27 Jenken Bioscience, Inc. Chromones et derives de chromones, et utilisations de ceux-ci
WO2007010342A1 (fr) * 2005-07-15 2007-01-25 Sahajanand Biotech Private Limited Dispositifs medicaux implantables comprenant un flavonoide ou un derive de celui-ci pour la prevention de la restenose
WO2007016525A2 (fr) * 2005-07-29 2007-02-08 Resverlogix Corp. Compositions pharmaceutiques pour la prevention et le traitement de maladies complexes et leur administration par des dispositifs medicaux inserables
EP2045241A1 (fr) 2002-01-24 2009-04-08 Merck Frosst Canada Ltd. Cycloalkanoindoles substitues par un fluor et leur utilisation comme antagonistes du recepteur de prostaglandine D2
EP1009404A4 (fr) * 1997-05-13 2009-07-01 Octamer Inc Procede de traitement de l'inflammation ou de maladies inflammatoires a l'aide d'inhibiteurs de poly-adp ribose polymerase
WO2009118338A2 (fr) * 2008-03-27 2009-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Utilisation d’un composé de type polyphénolique pour prévenir ou traiter une maladie neurodégénérative d’expansion de polyglutamine
US7678798B2 (en) 2004-04-13 2010-03-16 Incyte Corporation Piperazinylpiperidine derivatives as chemokine receptor antagonists
WO2010031183A1 (fr) 2008-09-22 2010-03-25 Merck Frosst Canada Ltd. Dérivés d'indole comme antagonistes du récepteur crth2
US7700624B2 (en) 2005-12-21 2010-04-20 Incyte Corporation 3-aminocyclopentanecrboxamides as modulators of chemokine receptors
WO2010061329A1 (fr) 2008-11-26 2010-06-03 Pfizer Inc. 3-aminocyclopentanecarboxamides en tant que modulateurs des récepteurs de chimiokines
WO2010090764A1 (fr) 2009-02-09 2010-08-12 Supergen, Inc. Inhibiteurs pyrrolopyrimidinyle de l'axi kinase
CN1837202B (zh) * 2006-04-25 2010-08-18 中国人民解放军第二军医大学 具有降血脂作用的黄酮醇类化合物
EP2277872A1 (fr) * 2005-05-31 2011-01-26 Promega Corporation Composés luminogènes et fluorogènes et procédés pour la détection de molécules ou de conditions
CN102274237A (zh) * 2011-06-16 2011-12-14 成都中医药大学 黄酮类化合物的新用途
US8106052B2 (en) 2002-09-20 2012-01-31 Promega Corporation Luminescence-based methods and probes for measuring cytochrome P450 activity
US8114995B2 (en) 2008-06-26 2012-02-14 Resverlogix Corp. Methods of preparing quinazolinone derivatives
WO2012051036A1 (fr) 2010-10-11 2012-04-19 Merck Sharp & Dohme Corp. Composés de type quinazolinone convenant comme antagonistes de crth2
WO2012087861A1 (fr) 2010-12-23 2012-06-28 Merck Sharp & Dohme Corp. Quinoxalines et aza-quinoxalines comme modulateurs du récepteur crth2
EP2492267A1 (fr) 2009-02-24 2012-08-29 Merck Sharp & Dohme Corp. Dérivés d'indole en tant qu'antagonistes du récepteur CRTH2 en combination avec un second principe actif
US8288559B2 (en) 2008-08-18 2012-10-16 Promega Corporation Luminogenic compounds and methods to detect cytochrome P450 3A enzymes
WO2012151137A1 (fr) 2011-05-04 2012-11-08 Merck Sharp & Dohme Corp. Inhibiteurs de tyrosine kinase splénique contenant une aminopyridine
WO2012174176A1 (fr) 2011-06-17 2012-12-20 Merck Sharp & Dohme Corp. Tétrahydroquinolines à fusion cycloalkyle en tant que modulateurs de l'activité du récepteur crth2
WO2013052393A1 (fr) 2011-10-05 2013-04-11 Merck Sharp & Dohme Corp. Inhibiteurs de tyrosine kinase de la rate (syk) contenant un 3-pyridyl carboxamide
US8952021B2 (en) 2009-01-08 2015-02-10 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
JP2015134809A (ja) * 2008-09-29 2015-07-27 サートリス ファーマシューティカルズ， インコーポレイテッド サーチュインモジュレーターとしてのクロメノンアナログ
EP2910945A1 (fr) * 2008-09-30 2015-08-26 Case Western Reserve University Sondes moléculaires pour l'imagerie de la myéline
US9199990B2 (en) 2007-02-01 2015-12-01 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular diseases
US9238640B2 (en) 2009-03-18 2016-01-19 Resverlogix Corp. Anti-inflammatory agents
US9271978B2 (en) 2012-12-21 2016-03-01 Zenith Epigenetics Corp. Heterocyclic compounds as bromodomain inhibitors
WO2016123141A1 (fr) * 2015-01-26 2016-08-04 Berreau Lisa M Molécules libérant du monoxyde de carbone et méthodes associées
US9610251B2 (en) 2011-11-01 2017-04-04 Resverlogix Corp. Pharmaceutical compositions for substituted quinazolinones
US9757368B2 (en) 2009-04-22 2017-09-12 Resverlogix Corp. Anti-inflammatory agents
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
US9790537B2 (en) 2014-01-29 2017-10-17 Promega Corporation Quinone-masked probes as labeling reagents for cell uptake measurements
KR101837690B1 (ko) * 2016-04-04 2018-03-13 한국한의학연구원 고량강 추출물, 이의 분획물 또는 고량강으로부터 분리된 화합물 갈란진을 유효성분으로 포함하는 혈관 재협착 예방 또는 치료용 조성물
US9963476B2 (en) 2015-02-19 2018-05-08 Council Of Scientific And Industrial Research Antioxidant compound having anti atherosclerotic effect and preparation thereof
WO2018099675A1 (fr) * 2016-11-30 2018-06-07 Beiersdorf Ag Utilisation de 2'-méthoxyflavones dans des préparations cosmétiques ou dermatologiques pour la prophylaxie et le traitement des peaux sensibles
US10111885B2 (en) 2015-03-13 2018-10-30 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
CN109265424A (zh) * 2018-09-25 2019-01-25 天津中医药大学 一种黄酮类衍生物及其制备方法和鉴定方法
WO2020143793A1 (fr) 2019-01-10 2020-07-16 石药集团中奇制药技术（石家庄）有限公司 Sels de composé hétérocyclique et utilisation associée

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115160279B (zh) * 2022-07-27 2023-11-24 中国药科大学 苯并吡喃酮类化合物、药物组合物和应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1175808A (en) * 1967-11-24 1969-12-23 Laroche Navarron Lab Improvements in or relating to new Therapeutic Composition, new Coumarin Derivatives and their process of preparation
FR2244493A1 (en) * 1973-08-09 1975-04-18 Pluripharm Flavonoid amino-acid salts - for treatment of haemorrhage, circulatory disorders and atherosclerosis
DE3601417A1 (de) * 1986-01-20 1987-07-23 Nattermann A & Cie 2'-alkyl-(alkenyl-) substituierte quercetine
EP0347864A2 (fr) * 1988-06-24 1989-12-27 Andries Johannes Cornelus Strydom Agents antiathérogéniques
US5242397A (en) * 1989-06-20 1993-09-07 Cedars-Sinai Medical Center Catheter device and method of use for intramural delivery of protein kinase C and tyrosine protein kinase inhibitors to prevent restenosis after balloon angioplasty
EP0564350A1 (fr) * 1992-03-31 1993-10-06 Adir Et Compagnie Nouvelles 3',5'-ditertbutyl-4'-hydroxy flavones, leur procédé de préparation et les compositions pharmaceutiques exerçant une activité anti-oxydante et anti-vasoconstrictrice
EP0633022A2 (fr) * 1993-07-09 1995-01-11 Kureha Chemical Industry Co., Ltd. Flavones chondroprotectives

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1175808A (en) * 1967-11-24 1969-12-23 Laroche Navarron Lab Improvements in or relating to new Therapeutic Composition, new Coumarin Derivatives and their process of preparation
FR2244493A1 (en) * 1973-08-09 1975-04-18 Pluripharm Flavonoid amino-acid salts - for treatment of haemorrhage, circulatory disorders and atherosclerosis
DE3601417A1 (de) * 1986-01-20 1987-07-23 Nattermann A & Cie 2'-alkyl-(alkenyl-) substituierte quercetine
EP0347864A2 (fr) * 1988-06-24 1989-12-27 Andries Johannes Cornelus Strydom Agents antiathérogéniques
US5242397A (en) * 1989-06-20 1993-09-07 Cedars-Sinai Medical Center Catheter device and method of use for intramural delivery of protein kinase C and tyrosine protein kinase inhibitors to prevent restenosis after balloon angioplasty
EP0564350A1 (fr) * 1992-03-31 1993-10-06 Adir Et Compagnie Nouvelles 3',5'-ditertbutyl-4'-hydroxy flavones, leur procédé de préparation et les compositions pharmaceutiques exerçant une activité anti-oxydante et anti-vasoconstrictrice
EP0633022A2 (fr) * 1993-07-09 1995-01-11 Kureha Chemical Industry Co., Ltd. Flavones chondroprotectives

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AM. J. PATHOLOGY, vol. 147, no. 2, 2 August 1995, pages 278-292, XP000575649 M.E. GERRITSEN ET AL.: "Flavonoids inhibit cytokine.induced endothelial cell adhesion protein gene expression" *
BR. J. PHARMACOL., vol. 111, no. 2, 1994, pages 578-581, XP000575658 S. TRANCHINA ET AL.: "Inhibition of human monocyte adhesion to endothelial cells by the coumarin derivative, chloricromene" *
INT. ARCH. ALLERGY IMMUNOL., vol. 107, no. 1-3, 13 July 1995, pages 435-436, XP000576204 E. MIDDLETON ET AL.: "Quercetin inhibits lipopolysaccharide-induced expression of endothelial cell intracellular adhesion molecule-1" & Conference on "Molecular and Clinical Implications for Allergy in the 21st Century" in Nantucket, Massachusetts September 25-29, 1994 *
NED. TIJDSCHR. GENEESKD., vol. 119, no. 117, 26 April 1975, pages 673-677, XP000575659 A. DE NEELING: "Coumarine bij atherosclerose" *
PHARM. WEEKBL. SCI., vol. 6, no. 1, 24 February 1984, pages 27-31, XP000575665 H.K. NIEUWENHUIS ET AL.: "Agents interfering with the platelet-vessel wall interaction" *
POL. J. PHARMACOL. PHARM., vol. 29, no. 1, 1977, pages 7-10, XP000575657 E. SEMPINSKA ET AL.: "Effect of flavonoids on the platelet adhesivness in repeatedly bred rats" *

Cited By (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1009404A4 (fr) * 1997-05-13 2009-07-01 Octamer Inc Procede de traitement de l'inflammation ou de maladies inflammatoires a l'aide d'inhibiteurs de poly-adp ribose polymerase
US6221888B1 (en) 1997-05-29 2001-04-24 Merck & Co., Inc. Sulfonamides as cell adhesion inhibitors
US6291511B1 (en) 1997-05-29 2001-09-18 Merck & Co., Inc. Biarylalkanoic acids as cell adhesion inhibitors
US5922719A (en) * 1997-08-11 1999-07-13 Warner-Lambert Company Coumarin dopamine D4 receptor antagonists
US6069163A (en) * 1997-10-21 2000-05-30 Merck & Co., Inc. Azapeptide acids as cell adhesion inhibitors
US6020347A (en) * 1997-11-18 2000-02-01 Merck & Co., Inc. 4-substituted-4-piperidine carboxamide derivatives
US6191171B1 (en) 1997-11-20 2001-02-20 Merck & Co., Inc. Para-aminomethylaryl carboxamide derivatives
US6090841A (en) * 1997-11-21 2000-07-18 Merck & Co., Inc. Substituted pyrrole derivatives as cell adhesion inhibitors
US6645939B1 (en) 1997-11-24 2003-11-11 Merck & Co., Inc. Substituted β-alanine derivatives as cell adhesion inhibitors
WO1999054286A3 (fr) * 1998-04-17 2000-05-04 Wayne Hughes Inst Inhibiteurs btk et leurs procedes d'identification et d'utilisation
WO1999054286A2 (fr) * 1998-04-17 1999-10-28 Parker Hughes Institute Inhibiteurs btk et leurs procedes d'identification et d'utilisation
WO2000003706A1 (fr) * 1998-07-15 2000-01-27 Laboratoire L. Lafon Composition therapeutique a base de flavonoïdes destinee a etre utilisee dans le traitement des tumeurs par des agents cytotoxiques
FR2781153A1 (fr) * 1998-07-15 2000-01-21 Lafon Labor Composition therapeutique a base de flavonoides destinee a etre utilisee dans le traitement des tumeurs par des agents cytotoxiques
US6303652B1 (en) 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
US6221900B1 (en) 1998-08-21 2001-04-24 Hughes Institute BTK inhibitors and methods for their identification and use
US6753348B2 (en) 1998-08-21 2004-06-22 Parker Hughes Institute BTK inhibitors and methods for their identification and use
US6294575B1 (en) 1998-08-21 2001-09-25 Parker Hughes Institute BTK inhibitors and methods for their identification and use
US6160010A (en) * 1998-08-21 2000-12-12 Parker Hughes Institute BTK inhibitors and methods for their identification and use
US6365626B1 (en) 1998-08-21 2002-04-02 Parker Hughes Institute BTK inhibitors and methods for their identification and use
US6509368B1 (en) * 1998-10-02 2003-01-21 Gruenenthal Gmbh Use of catechol derivatives as proteinase inhibitors
WO2000019989A3 (fr) * 1998-10-02 2000-11-09 Gruenenthal Gmbh Utilisation de derives de catechine comme inhibiteurs de proteinase
WO2000019989A2 (fr) * 1998-10-02 2000-04-13 Grünenthal GmbH Utilisation de derives de catechine comme inhibiteurs de proteinase
DE19845372A1 (de) * 1998-10-02 2000-04-20 Gruenenthal Gmbh Verwendung von Katecholderivaten als Proteinaseninhibitoren
AU766379B2 (en) * 1998-10-02 2003-10-16 Grunenthal Gmbh Use of catechol derivatives as proteinase inhibitors
WO2000035435A1 (fr) * 1998-12-15 2000-06-22 Warner-Lambert Company Technique de prevention du rejet de greffe par utilisation d'un inhibiteur du mek
US6331562B1 (en) 1998-12-30 2001-12-18 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
US6291456B1 (en) 1998-12-30 2001-09-18 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
WO2000050030A1 (fr) * 1999-02-25 2000-08-31 Ted Ebendal Nouvelle utilisation
JP2004509855A (ja) * 2000-07-21 2004-04-02 中外製薬株式会社 ＴＮＦαインヒビターとして有用なクマリン誘導体
EP1368024A1 (fr) * 2001-03-16 2003-12-10 Novogen Research Pty. Ltd. Traitement de la restenose
EP1368024A4 (fr) * 2001-03-16 2009-03-18 Novogen Res Pty Ltd Traitement de la restenose
WO2002102368A1 (fr) * 2001-06-19 2002-12-27 Tg Biotech, Inc. Procede de production cellulaire de masse de chondrocytes a l'aide d'un inhibiteur d'activite erk, et procede de criblage associe
WO2002102367A1 (fr) * 2001-06-19 2002-12-27 Tg Biotech, Inc. Composition pharmaceutique pour la prevention et le traitement de l'arthrite des articulations, et procede de criblage correspondant
EP2045241A1 (fr) 2002-01-24 2009-04-08 Merck Frosst Canada Ltd. Cycloalkanoindoles substitues par un fluor et leur utilisation comme antagonistes du recepteur de prostaglandine D2
EP2295409A1 (fr) 2002-01-24 2011-03-16 Merck Frosst Canada Limited Cycloalkanoindoles substitués par un fluor et leur utilisation comme antagonistes du récepteur de prostaglandine D2
JP2004123728A (ja) * 2002-09-09 2004-04-22 New Industry Research Organization 新規フラボノイド化合物及びその利用
US10408819B2 (en) 2002-09-20 2019-09-10 Promega Corporation Luminescence-based methods and probes for measuring cytochrome P450 activity
US8106052B2 (en) 2002-09-20 2012-01-31 Promega Corporation Luminescence-based methods and probes for measuring cytochrome P450 activity
US9574223B2 (en) 2002-09-20 2017-02-21 Promega Corporation Luminescence-based methods and probes for measuring cytochrome P450 activity
US8765969B2 (en) 2002-09-20 2014-07-01 Promega Corporation Luminescence-based methods and probes for measuring cytochrome P450 activity
EP1556031A2 (fr) * 2002-10-22 2005-07-27 Jenken Bioscience, Inc. Chromones et derives de chromones, et utilisations de ceux-ci
EP1556031A4 (fr) * 2002-10-22 2009-03-25 Jenken Biosciences Inc Chromones et derives de chromones, et utilisations de ceux-ci
WO2004041279A1 (fr) 2002-10-30 2004-05-21 Merck & Co., Inc. Modulateurs gamma-aminoamides de l'activite de recepteur de chimiokine
WO2004105769A1 (fr) * 2003-05-28 2004-12-09 Universite De Liege Composition pharmaceutique destinee au traitement et/ou a la prevention de l'atherosclerose d'origine infectieuse
US8680104B2 (en) 2004-04-13 2014-03-25 Incyte Corporation Piperazinylpiperidine derivatives as chemokine receptor antagonists
US7678798B2 (en) 2004-04-13 2010-03-16 Incyte Corporation Piperazinylpiperidine derivatives as chemokine receptor antagonists
US9067921B2 (en) 2004-04-13 2015-06-30 Incyte Corporation Piperazinylpiperidine derivatives as chemokine receptor antagonists
US8268826B2 (en) 2004-04-13 2012-09-18 Incyte Corporation Piperazinylpiperidine derivatives as chemokine receptor antagonists
US7951550B2 (en) 2005-05-31 2011-05-31 Promega Corporation Luminogenic and fluorogenic compounds and methods to detect molecules or conditions
US8476450B2 (en) 2005-05-31 2013-07-02 Promega Corporation Luminogenic and fluorogenic compounds and methods to detect molecules or conditions
US10745365B2 (en) 2005-05-31 2020-08-18 Promega Corporation Luminogenic and fluorogenic compounds and methods to detect molecules or conditions
US10077244B2 (en) 2005-05-31 2018-09-18 Promega Corporation Luminogenic and fluorogenic compounds and methods to detect molecules or conditions
EP2277872A1 (fr) * 2005-05-31 2011-01-26 Promega Corporation Composés luminogènes et fluorogènes et procédés pour la détection de molécules ou de conditions
GB2443576A (en) * 2005-07-15 2008-05-07 Sahajanand Biotech Private Ltd Implantable medical devices comprising a flavonoid or derivative thereof for prevention of restenosis
WO2007010342A1 (fr) * 2005-07-15 2007-01-25 Sahajanand Biotech Private Limited Dispositifs medicaux implantables comprenant un flavonoide ou un derive de celui-ci pour la prevention de la restenose
WO2007016525A2 (fr) * 2005-07-29 2007-02-08 Resverlogix Corp. Compositions pharmaceutiques pour la prevention et le traitement de maladies complexes et leur administration par des dispositifs medicaux inserables
WO2007016525A3 (fr) * 2005-07-29 2007-05-31 Resverlogix Corp Compositions pharmaceutiques pour la prevention et le traitement de maladies complexes et leur administration par des dispositifs medicaux inserables
EP2314295A1 (fr) * 2005-07-29 2011-04-27 Resverlogix, Inc Compositions pharmaceutiques pour la prevention et le traitement de maladies complexes et leur administration par des dispositifs medicaux inserables
JP2009502970A (ja) * 2005-07-29 2009-01-29 レスバーロジックス コーポレイション 複合疾患の予防および処置のための薬学的組成物および挿入可能な医療用デバイスによるその送達
US7700624B2 (en) 2005-12-21 2010-04-20 Incyte Corporation 3-aminocyclopentanecrboxamides as modulators of chemokine receptors
CN1837202B (zh) * 2006-04-25 2010-08-18 中国人民解放军第二军医大学 具有降血脂作用的黄酮醇类化合物
US9199990B2 (en) 2007-02-01 2015-12-01 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular diseases
US10532054B2 (en) 2007-02-01 2020-01-14 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular diseases
WO2009118338A2 (fr) * 2008-03-27 2009-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Utilisation d’un composé de type polyphénolique pour prévenir ou traiter une maladie neurodégénérative d’expansion de polyglutamine
WO2009118338A3 (fr) * 2008-03-27 2009-11-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Utilisation d’un composé de type polyphénolique pour prévenir ou traiter une maladie neurodégénérative d’expansion de polyglutamine
US8114995B2 (en) 2008-06-26 2012-02-14 Resverlogix Corp. Methods of preparing quinazolinone derivatives
US8288559B2 (en) 2008-08-18 2012-10-16 Promega Corporation Luminogenic compounds and methods to detect cytochrome P450 3A enzymes
WO2010031183A1 (fr) 2008-09-22 2010-03-25 Merck Frosst Canada Ltd. Dérivés d'indole comme antagonistes du récepteur crth2
JP2015134809A (ja) * 2008-09-29 2015-07-27 サートリス ファーマシューティカルズ， インコーポレイテッド サーチュインモジュレーターとしてのクロメノンアナログ
US9987379B2 (en) 2008-09-30 2018-06-05 Case Western Reserve University Molecular probes for imaging of myelin
US11382991B2 (en) 2008-09-30 2022-07-12 Case Western Reserve University Molecular probes for imaging of myelin
EP2910945A1 (fr) * 2008-09-30 2015-08-26 Case Western Reserve University Sondes moléculaires pour l'imagerie de la myéline
WO2010061329A1 (fr) 2008-11-26 2010-06-03 Pfizer Inc. 3-aminocyclopentanecarboxamides en tant que modulateurs des récepteurs de chimiokines
US8952021B2 (en) 2009-01-08 2015-02-10 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
WO2010090764A1 (fr) 2009-02-09 2010-08-12 Supergen, Inc. Inhibiteurs pyrrolopyrimidinyle de l'axi kinase
EP2492267A1 (fr) 2009-02-24 2012-08-29 Merck Sharp & Dohme Corp. Dérivés d'indole en tant qu'antagonistes du récepteur CRTH2 en combination avec un second principe actif
US10882828B2 (en) 2009-03-18 2021-01-05 Resverlogix Corp. Anti-inflammatory agents
US10131640B2 (en) 2009-03-18 2018-11-20 Resverlogix Corp. Anti-inflammatory agents
US11407719B2 (en) 2009-03-18 2022-08-09 Resverlogix Corp. Anti-inflammatory agents
US9238640B2 (en) 2009-03-18 2016-01-19 Resverlogix Corp. Anti-inflammatory agents
US9757368B2 (en) 2009-04-22 2017-09-12 Resverlogix Corp. Anti-inflammatory agents
WO2012051036A1 (fr) 2010-10-11 2012-04-19 Merck Sharp & Dohme Corp. Composés de type quinazolinone convenant comme antagonistes de crth2
WO2012087861A1 (fr) 2010-12-23 2012-06-28 Merck Sharp & Dohme Corp. Quinoxalines et aza-quinoxalines comme modulateurs du récepteur crth2
WO2012151137A1 (fr) 2011-05-04 2012-11-08 Merck Sharp & Dohme Corp. Inhibiteurs de tyrosine kinase splénique contenant une aminopyridine
CN102274237B (zh) * 2011-06-16 2012-12-05 成都中医药大学 黄酮类化合物的新用途
CN102274237A (zh) * 2011-06-16 2011-12-14 成都中医药大学 黄酮类化合物的新用途
WO2012174176A1 (fr) 2011-06-17 2012-12-20 Merck Sharp & Dohme Corp. Tétrahydroquinolines à fusion cycloalkyle en tant que modulateurs de l'activité du récepteur crth2
WO2013052393A1 (fr) 2011-10-05 2013-04-11 Merck Sharp & Dohme Corp. Inhibiteurs de tyrosine kinase de la rate (syk) contenant un 3-pyridyl carboxamide
US9610251B2 (en) 2011-11-01 2017-04-04 Resverlogix Corp. Pharmaceutical compositions for substituted quinazolinones
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
US9278940B2 (en) 2012-11-21 2016-03-08 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
US9271978B2 (en) 2012-12-21 2016-03-01 Zenith Epigenetics Corp. Heterocyclic compounds as bromodomain inhibitors
US9790537B2 (en) 2014-01-29 2017-10-17 Promega Corporation Quinone-masked probes as labeling reagents for cell uptake measurements
WO2016123141A1 (fr) * 2015-01-26 2016-08-04 Berreau Lisa M Molécules libérant du monoxyde de carbone et méthodes associées
US9963476B2 (en) 2015-02-19 2018-05-08 Council Of Scientific And Industrial Research Antioxidant compound having anti atherosclerotic effect and preparation thereof
US10111885B2 (en) 2015-03-13 2018-10-30 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
US10772894B2 (en) 2015-03-13 2020-09-15 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
KR101837690B1 (ko) * 2016-04-04 2018-03-13 한국한의학연구원 고량강 추출물, 이의 분획물 또는 고량강으로부터 분리된 화합물 갈란진을 유효성분으로 포함하는 혈관 재협착 예방 또는 치료용 조성물
WO2018099675A1 (fr) * 2016-11-30 2018-06-07 Beiersdorf Ag Utilisation de 2'-méthoxyflavones dans des préparations cosmétiques ou dermatologiques pour la prophylaxie et le traitement des peaux sensibles
CN109265424A (zh) * 2018-09-25 2019-01-25 天津中医药大学 一种黄酮类衍生物及其制备方法和鉴定方法
WO2020143793A1 (fr) 2019-01-10 2020-07-16 石药集团中奇制药技术（石家庄）有限公司 Sels de composé hétérocyclique et utilisation associée

Also Published As

Publication number Publication date
WO1996031206A3 (fr) 1996-12-12
AU5259296A (en) 1996-10-23

Similar Documents

Publication Publication Date Title
WO1996031206A2 (fr) Flavones et coumarines utilisees en tant qu'agents dans le traitement de l'atherosclerose
JP5877425B2 (ja) 細胞増殖および血管新生を特徴とする疾患を治療する組成物および方法
US5464871A (en) Aromatic nitro and nitroso compounds and their metabolites useful as anti-viral and anti-tumor agents
US5962516A (en) Immunosuppressive compounds and methods
WO1997031921A1 (fr) Composes et procedes de traitement immunosupressif
KR20010089171A (ko) 퀴나졸린 유도체
WO1994012184A1 (fr) Utilisation d'acide mycophenolique, de mofetile de mycophenolate ou d'un derive de ceux-ci pour inhiber la stenose
CA2190993C (fr) Agent protecteur pour organe ou tissu
AU4508601A (en) Inhibitors of collagen-induced platelet aggregation
WO2000035867A1 (fr) Nouveaux ligands d'un recepteur nucleaire
EP0774257B1 (fr) Dérivés de pipérazine et homopipérazine pour l'inhibition de l'adhésion et l'infiltration cellulaire
CA2135312C (fr) Utilisation d'inhibiteurs de la 3-hydroxy-3-methylglutaryl coenzyme a-reductase comme methode de traitement du cancer
US20130157986A1 (en) Novel methylenedioxy phenolic compounds and their use to treat disease
US6034110A (en) Method for preventing onset of restenosis after angioplasty employing an RXR-specific retinoid and a PPARγ ligand
AU2001281134B2 (en) Methods of treating cancer and the pain associated therewith using endothelin antagonists
JP2930281B2 (ja) 皮膚疾患処置用薬剤
EA002435B1 (ru) Способ снижения уровня липопротеина (а) в сыворотке или в плазме крови млекопитающих
US5747528A (en) Chroman derivatives as anti-oxidants
US5789439A (en) Pharmaceutical use of forskolin derivatives
US5895785A (en) Treatment and prevention of disorders mediated by LA-paf or endothelial cells
US6166074A (en) Pharmaceutical compositions
US7432306B2 (en) Method for preparing novel transcription factors and use
US5378692A (en) Method of lowering lipids
US4532254A (en) Inhibitor of aldose reductase
EP0250814B1 (fr) Composition prophylactique et guérissante contenant un composé de la 8-chlorobenzothiazépine et son utilisation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BG CA CN CZ EE GE HU JP KR LT LV MX NO NZ PL RO SG SI SK UA UZ AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU BG CA CN CZ EE GE HU JP KR LT LV MX NO NZ PL RO SG SI SK UA UZ AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: CA